Lecithin
Other supplementAlso called · 3 names▾▴
lecithins, lecithin supplement, phosphatidylcholine
Lecithin supplement (plugged milk ducts)
Herbs and supplements are not FDA-approved before sale. About these sources
- Other
Research strength: 1 / 5
EMA's final assessment says oral soya-bean lecithin herbal medicines are not recommended during pregnancy because safety has not been established and data are insufficient. This advice applies to the soya-bean medicinal product, not sunflower lecithin or ordinary foods. A randomized trial tested phosphatidylcholine, one part of lecithin, from 18 weeks; a 2025 systematic review also reported no effect on its infant cognitive outcomes. That trial did not test whole lecithin or establish first-trimester outcomes. Evidence is insufficient for the first trimester. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 1 / 5
EMA's final assessment says oral soya-bean lecithin herbal medicines are not recommended during pregnancy because safety has not been established and data are insufficient. This advice applies to the soya-bean medicinal product, not sunflower lecithin or ordinary foods. A randomized trial tested phosphatidylcholine, one part of lecithin, from 18 weeks; a 2025 systematic review also reported no effect on its infant cognitive outcomes. That trial did not test whole lecithin or establish pregnancy outcomes by trimester. Evidence is insufficient for the second trimester. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 1 / 5
EMA's final assessment says oral soya-bean lecithin herbal medicines are not recommended during pregnancy because safety has not been established and data are insufficient. This advice applies to the soya-bean medicinal product, not sunflower lecithin or ordinary foods. A randomized trial tested phosphatidylcholine, one part of lecithin, from 18 weeks; a 2025 systematic review also reported no effect on its infant cognitive outcomes. The trial did not report trimester-specific results or test whole lecithin. Evidence is insufficient for the third trimester. Ask your provider about your situation.
Last reviewed: 2026-10-16
Lecithin — Breastfeeding
Research strength: 1 / 5
ABM says 5 to 10 g per day of soy or sunflower lecithin by mouth may be taken for duct inflammation, with a strength C recommendation. LactMed reports no scientifically valid clinical studies establishing the safety or effectiveness of high-dose lecithin in nursing mothers or infants. The primary 2003 study added soy lecithin directly to human milk in a feeding pump, rather than testing an oral supplement or duct treatment, and a 2023 commentary says the oral recommendation lacks an evidence base. EMA advises against lactation use of oral soya-bean lecithin herbal medicines because safety has not been established and data are insufficient; this advice does not cover sunflower lecithin. Evidence does not establish benefit or infant effects for high-dose oral supplementation. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- LactMed (NIH): LecithinUS government
- Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, revised 2022Professional society
- Chan et al. 2003: Lecithin decreases human milk fat loss during enteral pumpingUS government
- Douglas 2023 commentary on ABM Clinical Protocol #36US government
- EMA: Final assessment report on Glycine max (L.) Merr., lecithinumEU agencyEuropean guidance
Pregnancy
The EMA's final 2017 HMPC assessment covers oral soya-bean lecithin herbal medicines. It states that safety during pregnancy and lactation has not been established and that use is not recommended in the absence of sufficient data. This is a lack-of-data precaution for a soy medicinal product, not evidence of demonstrated fetal harm, and does not cover sunflower lecithin or ordinary food amounts. No human study of whole lecithin supplementation with pregnancy outcomes was identified in this review. Cheatham et al. 2012 randomized 140 pregnant women to phosphatidylcholine, one component of lecithin, or placebo from 18 weeks through 90 days postpartum; 99 infants were assessed at 10 and 12 months. The groups did not differ significantly on the measured global development, language, visuospatial memory, or episodic memory measures. Gould et al. 2025 also reviewed this trial and reported no effect on its measured outcomes. The review concluded that evidence on prenatal choline and child neurodevelopment remains insufficient. The study was not a whole-lecithin trial and did not establish pregnancy safety or report pregnancy outcomes by trimester.
Breastfeeding
LactMed reports no scientifically valid clinical studies of high-dose lecithin supplementation in nursing mothers or infants, no published information on milk levels of lecithin after maternal supplementation, and no relevant published infant-level or infant-effect information. ABM Protocol #36 says oral sunflower or soy lecithin may be taken for duct inflammation and gives the recommendation strength C. Douglas's 2023 commentary disputes the evidence base for that oral recommendation. The primary study cited by ABM, Chan et al. 2003, added soy lecithin directly to donated milk during pump delivery; it did not test a nursing parent's oral supplement or treatment of plugged ducts. The separate Cheatham trial tested phosphatidylcholine, not whole lecithin, and did not isolate effects from breast-milk exposure.
LactMed describes lecithin as a mixture that includes choline, choline esters, fatty acids, glycerol, glycolipids, triglycerides, phosphoric acid, and phospholipids such as phosphatidylcholine. Phosphatidylcholine is one component, not another name for the whole mixture. The EMA report defines its medicinal product as de-oiled phospholipids from soya bean; the ABM recommendation also names sunflower lecithin. Evidence about the soy medicinal product should not be generalized to sunflower lecithin or ordinary food lecithin.
What was tested
Chan et al. 2003 used donated mature milk from six mothers. Researchers added 0.5 g or 1 g soy lecithin per 50 mL milk before pumping it through an enteral feeding pump for at least four hours. Average fat loss was 58% in control samples, 55% with 0.5 g, and 2% with 1 g soy lecithin. This was a milk-delivery experiment, not an oral supplement or plugged-duct clinical trial, and it did not measure infant effects. Cheatham et al. 2012 conducted a double-blind randomized trial in 140 pregnant women, starting at 18 weeks and continuing through 90 days postpartum; 99 infants were assessed at 10 and 12 months. The abstract summarizes the supplement as 750 mg phosphatidylcholine, but the Methods specify 750 mg choline per day supplied in six capsules, each containing 833 mg phosphatidylcholine. No significant group differences were found in the measured infant cognitive outcomes. The trial tested a component of lecithin, not whole lecithin. It was supported by the Gerber Foundation, NIH grants, and the Egg Nutrition Center; Solae LLC supplied supplements. Gould et al. 2025 reviewed four randomized trials and five observational studies of prenatal choline, including the Cheatham trial; its conclusion concerns choline, not whole lecithin. Mitchell and Johnson's 2020 PubMed abstract describes a perspective reviewing practice experience, not a controlled efficacy trial.
Whether oral lecithin is an evidence-supported option for plugged milk ducts
- Source A says
- ABM says 5 to 10 g daily of oral sunflower or soy lecithin may be taken for duct inflammation and milk emulsification, with recommendation strength C. (Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, revised 2022)
- Source B says
- LactMed reports no scientifically valid clinical studies establishing the effects or effectiveness of high-dose lecithin supplementation in nursing mothers or infants. Douglas's commentary says the oral lecithin recommendation lacks an evidence base. The Chan study added lecithin directly to milk for pump delivery rather than testing oral use. (LactMed (NIH): Lecithin, Douglas 2023: Commentary on ABM Clinical Protocol #36, Chan et al. 2003: Lecithin decreases human milk fat loss during enteral pumping)
- Why they differ
- ABM presents a low-strength clinical option, while the commentary evaluates whether the cited studies support oral use for duct inflammation. The primary pump study did not test oral lecithin or plugged-duct treatment, and the 2020 paper cited in the protocol is a perspective about practice experience rather than a controlled trial.
- What the evidence shows overall
- The ABM statement is a clinical recommendation, not proof of benefit. The primary studies reviewed do not establish that oral lecithin treats plugged ducts or determine infant effects from high-dose maternal supplementation. Evidence remains insufficient.
- ABM says 5 to 10 g daily by mouth of sunflower or soy lecithin may be taken to reduce duct inflammation and emulsify milk; the protocol assigns recommendation strength C. (Academy of Breastfeeding Medicine Clinical Protocol #36)
- EMA says oral soya-bean lecithin herbal medicines are not recommended during pregnancy and lactation when data are insufficient and safety has not been established. (European Medicines Agency)
General research, not specific to pregnancy.
LactMed describes lecithin as usually well tolerated. EMA's limited clinical experience with oral soya-bean lecithin medicines includes gastrointestinal discomfort and hypersensitivity reactions, with unknown frequency; this information is specific to those medicines.
- LactMed says lecithin is usually well tolerated, while noting that high-dose supplementation has not been studied in valid clinical trials in nursing mothers or infants. (LactMed (NIH): Lecithin)
- For oral soya-bean lecithin herbal medicines, EMA reports limited clinical experience with gastrointestinal discomfort and hypersensitivity reactions; the frequency of these effects is not known. (EMA: Final assessment report on Glycine max (L.) Merr., lecithinum)
- LactMed (NIH): LecithinUS governmentSecondaryPage dated 2026-07-15Independent check
- Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, revised 2022Professional societySecondary
- EMA: Final assessment report on Glycine max (L.) Merr., lecithinumEU agencySecondaryPage dated 2017-01-31Independent checkEuropean guidance
- Douglas 2023: Commentary on ABM Clinical Protocol #36US governmentSecondaryPage dated 2023-12-12Independent check
- Mitchell and Johnson 2020: Breast Pathology That Contributes to Dysfunction of Human Lactation: a Spotlight on Nipple BlebsUS governmentSecondaryIndependent check
- Chan et al. 2003: Lecithin decreases human milk fat loss during enteral pumpingUS governmentPrimaryIndependent check
- Cheatham et al. 2012: Phosphatidylcholine supplementation in pregnant women consuming moderate-choline dietsUS governmentPrimary
- Gould et al. 2025: Choline During Pregnancy and Child NeurodevelopmentUS governmentPrimaryIndependent check
Last reviewed 2026-10-16
Independent check 2026-10-16
Not yet clinician-reviewed
Ask your provider about your situation.